Tirzepatide Provider Comparison
Comparison matrix
Prices 35 verified of 86 Rubric v1.0-draft Prices verified 0 of 86 Evidence records 90 verified Corrections open log

News · FDA and regulation

FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products

The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.

Event date 2026-02-06 · Published 2026-07-24 ·

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published Updated Sources captured Medically reviewed not yet — why

Direct answer

The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later. Event dated 2026-02-06; published 2026-07-24. Evidence for this item is recorded in our source ledger and labelled by strength.

Answer last reviewed: 2026-07-26Evidence:

What was announced

On 6 February 2026 the FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients that continue to be used in non-FDA-approved compounded products, and to address misleading direct-to-consumer advertising.

Framed at the time as an escalation, it reads in retrospect as the announcement of a strategy. The 503B bulks exclusion proposal followed on 30 April.

Why the shift mattered

Enforcement to that point had been letter-based. More than 55 warning letters went to online sellers in September 2025, and more than 40 to telehealth-based compounding pharmacies later that year. Compliance observers described the effect as limited — providers largely continued advertising and compounding, reframing products as patient-specific variants.

Letters address individual actors one at a time. Restricting the active ingredient addresses the supply. That is a structural intervention rather than an enforcement one, and it is what the bulks proposal delivers.

The sequence, assembled

  • October 2024 — tirzepatide shortage determined resolved, then remanded for reevaluation amid litigation.
  • February 2025 — semaglutide shortage resolved.
  • March 2025 — court denies preliminary injunction in Outsourcing Facilities Association v. FDA.
  • May 2025 — enforcement discretion window for 503B semaglutide closes.
  • September 2025 — 55+ warning letters.
  • Late 2025 — 40+ further letters.
  • February 2026 — API restriction announced; TrumpRx launches the day before.
  • Early 2026 — 30 more letters, with explicit legal threat.
  • April 2026 — 503B bulks exclusion proposed.
  • June 2026 — 25 more letters; comment period extended.

Nothing in that list is ambiguous about direction.

What it means for a patient reading provider marketing

Providers describing the regulatory position as unsettled, or the compounded market as continuing indefinitely, are describing a position the agency has been publicly closing for two years.

That does not make compounded medicine unlawful today, and it does not make a provider dishonest for supplying it. It does mean a twelve-month prepayment is a bet on a regulatory outcome, and a provider who will not say so is selling certainty they do not have.

If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.

How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.
What each step actually changedPrimary sources · captured 2026-07-26
What each step actually changed
DateWhat happenedEffect on compounded access
2022Tirzepatide added to the FDA drug shortage listA shortage listing is what permitted compounders to make copies of the approved product.
2024-10FDA declared the tirzepatide shortage resolvedRemoving the shortage listing removed one of the two legal pathways for compounding tirzepatide.
2025-02FDA declared the semaglutide shortage resolvedThe same pathway closed for semaglutide four months later.
2025-09-16FDA issued 55+ warning letters to online GLP-1 sellersLetters cited misleading direct-to-consumer advertising of compounded GLP-1 products.
2026-02-09Novo Nordisk sued Hims & Hers over compounded semaglutidePatent infringement claim following the launch of a low-cost compounded oral product.
2026-03-03FDA released 30 further warning letters to telehealth firmsTargeting claims that compounded GLP-1s are equivalent to the branded products.
2026-03-09Hims & Hers settled with Novo Nordisk and pivoted to branded supplyHims agreed to offer branded semaglutide and cease most compounded GLP-1 marketing. The largest compounded seller in the category left it. This changes who is actually in the compounded market.
2026-04-30FDA proposed excluding tirzepatide from the 503B bulks listThe agency found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk drug substances. This proposal targets the second and last remaining pathway.
2026-05-01Formal notice published at 91 Fed. Reg. 23431Docket 2026-08552 sets out the agency's substance-by-substance reasoning.
2026-06-26Comment period extended to 30 July 2026FDA granted an extension after a request for more time to respond. Comments inform, but do not bind, the final determination.
2026-07-30Comment period closesAfter this date the agency considers submissions before making a final determination. No final determination had published as of 24 July 2026.
A proposal is not a final rule. Nothing here says compounded tirzepatide is unlawful today.
503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.
Captured pricing at publication. Unverified rows sink on any sort.
ProviderProgramFormulationDose coverageMedicationRequired feesAll-in monthlyPrice typeEvidenceCaptured
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
Oak Longevityprepaidcompounded injectableflat at all covered doses———not capturedthird_party2026-07-06
Shedprepaidcompounded injectable—$245—$245Commitment tierReported2026-07-06
Enhance.MDprepaidcompounded injectable—$280—$280Commitment tierReported2026-07-06
Edenmonth_to_monthcompounded injectableflat at all covered doses$298—$298RecurringReported2026-07-06
Noom Medprepaidcompounded injectable—$299—$299Commitment tierReported2026-07-06
TrimRxmonth_to_monthcompounded injectableflat at all covered doses$349$0$349RecurringReported2026-07-06
MEDVimonth_to_monthcompounded injectable————Recurringthird_party—
bmiMDmonth_to_monthcompounded injectable—$399—$399RecurringReported2026-07-06
Enhance.MDprepaidcompounded microdose—$169—$169Commitment tierReported2026-07-06
Shedprepaidcompounded microdose—$199—$199Commitment tierReported2026-07-06
bmiMDmonth_to_monthcompounded microdose—$349—$349RecurringReported2026-07-06
Henry Medsprepaidcompounded oral / ODT————not capturedthird_party2026-07-06
Shedprepaidcompounded microdose—$149—$149Commitment tierReported2026-07-06
Oak Longevityprepaidcompounded injectableflat at all covered doses———not capturedthird_party2026-07-06
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
Shedprepaidcompounded injectable—$175—$175Commitment tierReported2026-07-06
Edenmonth_to_monthcompounded injectableflat at all covered doses$198—$198RecurringReported2026-07-06
Noom Medprepaidcompounded injectable—$199—$199Commitment tierReported2026-07-06
TrimRxmonth_to_monthcompounded injectableflat at all covered doses$199$0$199RecurringReported2026-07-06
Enhance.MDprepaidcompounded injectable—$212—$212Commitment tierReported2026-07-06
bmiMDmonth_to_monthcompounded injectable—$289—$289RecurringReported2026-07-06
Henry Medsmonth_to_monthcompounded injectable————not capturedthird_party2026-07-06
MEDVimonth_to_monthcompounded injectable—$299—$299RecurringReported2026-07-06
Henry Medsmonth_to_monthcompounded sublingual————not capturedthird_party2026-07-06
Shedmonth_to_monthcompounded sublingual—$199—$199RecurringReported2026-07-06
Shedprepaidcompounded sublingual—$229—$229Commitment tierReported2026-07-06
Henry Medsprepaidcompounded oral / ODT————not capturedthird_party2026-07-06
MEDVimonth_to_monthcompounded oral / ODT————Recurringthird_party—
Foundprepaidcompounded injectableflat at all covered doses$169—$169Commitment tierReported2026-07-06
Henry Medsmonth_to_monthcompounded injectable————not capturedthird_party2026-07-06
LillyDirectmanufacturer_directbrand oral, FDA-approved—$149—$149RecurringReported2026-07-06
NovoCare Pharmacymanufacturer_directbrand oral, FDA-approved—$149—$149RecurringReported2026-07-06
LillyDirectmanufacturer_directbrand injectable, FDA-approved—$299—$299RecurringReported2026-07-06
NovoCare Pharmacymanufacturer_directbrand injectable, FDA-approved—$349—$349Advertised startingReported2026-07-06
PlushCaremonth_to_monthbrand injectable, FDA-approved—$319—$319RecurringReported2026-07-06
WeightWatchers Clinicprepaidbrand injectable, FDA-approved—$323—$323Commitment tierReported2026-07-06
Himsmonth_to_monthbrand oral, FDA-approved—$298—$298RecurringReported2026-07-06
Romonth_to_monthbrand injectable, FDA-approved—$348—$348RecurringReported2026-07-06
Foundprepaidbrand injectable, FDA-approved—$447—$447Commitment tierReported2026-07-06
Edenmonth_to_monthbrand injectable, FDA-approved—$1,794—$1,794RecurringReported2026-07-06
Hersmonth_to_monthbrand injectable, FDA-approved—$2,048—$2,048RecurringReported2026-07-06
Zappy Healthongoing—————RecurringNo public price—
Calibrateongoing—————RecurringNo public price—
Form Healthongoing—————RecurringNo public price—
IVIM Healthongoing—————RecurringNo public price—
Embodycompoundedcompounded injectable————not capturedthird_party—
SkinnyRxcompoundedcompounded injectable————not capturedthird_party—
Yucca Healthcompoundedcompounded injectable————not capturedthird_party—
Lavender Sky Healthcompoundedcompounded injectable————not capturedthird_party—
OrderlyMedscompoundedcompounded injectable————not capturedthird_party—
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
LillyDirectbrand directbrand Zepbound single-dose vialSelf Pay Journey Program—$0—RecurringVerified2026-07-27
Mochi Healthmembership plus medicationcompounded injectableAll published doses$199$1$200RecurringVerified2026-07-27
Mochi Healthmembership plus medicationcompounded injectableAll published doses$99$1$100RecurringVerified2026-07-27
Fifty 410pay per programmecompounded injectableStarting programme$133$0$133RecurringVerified2026-07-27
Trimiall-inclusivecompounded injectableNot stated$125$0$125RecurringVerified2026-07-27
Trimiall-inclusivecompounded injectableNot stated$235$0$235RecurringVerified2026-07-27
NexLife (opens nexlife.us in a new tab)">NexLife (opens nexlife.us in a new tab)all-inclusive flat ratecompounded injectableAll covered doses$215$0$215RecurringVerified2026-07-28
NexLife (opens nexlife.us in a new tab)">NexLife (opens nexlife.us in a new tab)all-inclusive flat ratecompounded injectableAll covered doses$195$0$195RecurringVerified2026-07-28
NexLife (opens nexlife.us in a new tab)">NexLife (opens nexlife.us in a new tab)all-inclusive flat ratecompounded injectableAll covered doses$190$0$190RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectableAll covered doses$186$0$186RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectableAll covered doses$165$0$165RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectableAll covered doses$149$0$149RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectableAll covered doses$147$0$147RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectableAll covered doses$145$0$145RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$189$0$189RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$159$0$159RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$150$0$150RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$147$0$147RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$129$0$129RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$117$0$117RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$114$0$114RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded injectable microdoseAll covered doses$110$0$110RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$229$0$229RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$219$0$219RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$205$0$205RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$199$0$199RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$199$0$199RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$185$0$185RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$177$0$177RecurringVerified2026-07-28
NexLifeall-inclusive flat ratecompounded sublingual ODTAll covered doses$165$0$165RecurringVerified2026-07-28

Questions readers actually ask

What did FDA announce in February 2026?

That it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded products, and address misleading advertising.

Did warning letters change behaviour?

Compliance observers described the earlier letters as having limited effect, with providers continuing to advertise and compound. The February announcement marked a shift to structural action.

Cite this pageCC BY 4.0

Tirzepatide Provider Comparison. “FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products.” S.J Partners LLC, 2026-07-26. https://tirzepatideprovidercomparison.com/news/fda-february-2026-api-restriction/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 86 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.

Comparing 0 of 4